S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:RXRX

Recursion Pharmaceuticals (RXRX) Earnings Date, Estimates & Call Transcripts

$8.63
+0.20 (+2.37%)
(As of 06/6/2023 ET)
Compare
Today's Range
$8.18
▼
$8.70
50-Day Range
$4.56
▼
$9.25
52-Week Range
$4.54
▼
$14.18
Volume
1.27 million shs
Average Volume
1.46 million shs
Market Capitalization
$1.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.40
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Aug. 8Estimated
Actual EPS
(May. 8)
-$0.34 Beat By $0.01
Consensus EPS
(May. 8)
-$0.35
Last Year's Q2 EPS
(5/10/2022)
-$0.33
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RXRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RXRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Recursion Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.34)($0.33)($0.34)
Q2 20232($0.38)($0.36)($0.37)
Q3 20234($0.35)($0.34)($0.35)
Q4 20232($0.34)($0.17)($0.26)
FY 202310($1.41)($1.20)($1.31)
Q1 20241($0.33)($0.33)($0.33)
Q2 20241($0.33)($0.33)($0.33)
Q3 20241($0.35)($0.35)($0.35)
Q4 20241($0.83)($0.83)($0.83)
FY 20244($1.84)($1.84)($1.84)

RXRX Earnings Date and Information

Recursion Pharmaceuticals last issued its quarterly earnings data on May 8th, 2023. The reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.01. The business had revenue of $12.13 million for the quarter, compared to analyst estimates of $15.93 million. Recursion Pharmaceuticals has generated ($1.38) earnings per share over the last year (($1.38) diluted earnings per share). Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.41) to ($1.62) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off prior year's report dates.

Recursion Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/8/2023
(Estimated)		        
5/8/20233/31/2023($0.35)($0.34)+$0.01($0.34)$15.93 million$12.13 million
2/27/2023Q4 2022($0.15)($0.31)($0.16)($0.31)$66.68 million$13.68 million
11/8/2022Q3 2022($0.36)($0.35)+$0.01($0.35)$6.43 million$13.16 million
8/9/2022Q2 2022($0.35)($0.38)($0.03)($0.38)$5.60 million$7.67 million
5/10/2022Q1 2022$0.51($0.33)($0.84)($0.33)$152.90 million$5.33 million
3/23/2022Q4 2021($0.30)($0.38)($0.08)($0.38)$7.62 million$2.53 million
11/10/20219/30/2021($0.28)($0.28)($0.28)$2.62 million$2.53 million
8/12/20216/30/2021($0.23)($0.31)($0.08)($0.31)$2.65 million$2.55 million
5/12/20213/31/2021($0.24)($1.33)($1.09)($1.33)$2.56 million












Recursion Pharmaceuticals Earnings - Frequently Asked Questions

When is Recursion Pharmaceuticals's earnings date?

Recursion Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off last year's report dates. Learn more on RXRX's earnings history.

Did Recursion Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) reported ($0.34) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.35) by $0.01. Learn more on analysts' earnings estimate vs. RXRX's actual earnings.

How much revenue does Recursion Pharmaceuticals generate each year?

Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded annual revenue of $39.84 million.

How much profit does Recursion Pharmaceuticals generate each year?

Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded net income of -$239.48 million. RXRX has generated -$1.38 earnings per share over the last four quarters.

What is Recursion Pharmaceuticals's EPS forecast for next year?

Recursion Pharmaceuticals's earnings are expected to decrease from ($1.41) per share to ($1.62) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:RXRX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -